Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00923468 · ClinicalTrials.gov registry record
Pharmacokinetic Studies Participation Survey
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 25
- Enrollment target
NCT00923468: Completed study, sponsored by National Cancer Institute (NCI).
NCT00923468 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00923468 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
Background: * A pharmacokinetic (PK) study of a new drug involves taking several blood samples over a period of time from study participants to determine how the body handles the substance. These studies provide critical information about new drugs. * Often, patients or parents of children in drug studies choose not to participate in optional PK studies that are part of the study protocol. * A better understanding of why patients or families do or do not agree to participate in PK studies may help researchers make it easier for people to participate in them. Objectives: * To learn why some people do or do not agree to participate in PK blood sampling studies. Eligibility: * Patients 18 years of age and older and parents or guardians of children who are participating in a study of a drug that includes the option of participating in PK sampling. Design: * Participants fill out a 2-page survey asking about why they did or did not participate in the study's PK sampling.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-09-23 |
What the finished NCT00923468 record still lists
NCT00923468 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00923468 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00923468 about?
NCT00923468 is a clinical study titled "Pharmacokinetic Studies Participation Survey". Background: * A pharmacokinetic (PK) study of a new drug involves taking several blood samples over a period of time from study participants to determine how the body handles the substance. These studies provide critical information about new drugs. * Often, patients or parents of children in drug ...
What is the current status of trial NCT00923468?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2008-09-23.
Who is sponsoring clinical trial NCT00923468?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI